71.   The company plans to market the drug by the end of the July.

72.   The drug is marketed as Procardia by Pfizer Inc. of New York City and as Adalat by Bayer Co. of West Haven, Conn.

73.   The drug is marketed by London-based Glaxo Wellcome Plc under license from BioChem Pharma Inc. of Laval, Canada.

74.   The drug is marketed by Celgene Corp. of Warren, N.J.

75.   The drug is marketed in the U.S. by Roxanne Laboratories.

76.   The drug would be marketed by Hoffmann-La Roche, a unit of Roche Holding.

77.   The FDA sided with Genpharm, giving that company a one-month window to market the drug on an exclusive basis and rejecting the Novopharm license.

78.   The drug will be marketed, however, by Advances in Health Technology, an enterprise created by the Population Council.

79.   The London-based drugmaker is seeking U.S. Food and Drug Administration for clearance to market the drug for treating heart failure.

80.   The letter, sent by the FDA to the company in December, explained why the agency had declined to review an application to market the drug.